The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

Highlighting the event is the immersive simulation, “Seeing Beyond the Ordinary and Repairing Damages,” led by world-renowned ...

Viralgen and Axovia are set to form a partnership to progress the development and manufacturing of gene therapy for retinal ...

Early detection and monitoring are key to the diagnosis and management of ocular diseases, including glaucoma, retinal and ...

According to the American Academy of Ophthalmology, glaucoma is a group of eye conditions that damage the optic nerve, often ...

The implementation of AIDRSS offers transformative implications for DR screening in India, particularly in rural and ...

Mysuru: Mysuru district health authorities, in association with the District Blind Control Society, launched a mobile eye ...

Ocugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Data from continuous glucose monitors can predict nerve, eye and kidney damage caused by type 1 diabetes researchers have found. That suggests doctors may be able to use data from the devices to help ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...